Skip to main content
AAN.com

Abstract

Objective

To determine whether performance on the Free and Cued Selective Reminding Test (FCSRT) is associated with PET in vivo markers of brain pathology and whether it can distinguish those who will develop dementia later in life due to autosomal-dominant Alzheimer disease (AD) from age-matched controls.

Methods

Twenty-four cognitively unimpaired Presenilin-1 E280A carriers (mean age 36 years) and 28 noncarriers (mean age 37 years) underwent Pittsburg compound B-PET (amyloid), flortaucipir-PET (tau), and cognitive testing, including the FCSRT (immediate and delayed free and cued recall scores). Linear regressions were used to examine the relationships among FCSRT scores, age, mean cortical amyloid, and regional tau burden.

Results

Free and total recall scores did not differ between cognitively unimpaired mutation carriers and noncarriers. Greater age predicted lower free recall and delayed free and total recall scores in carriers. In cognitively impaired carriers, delayed free recall predicted greater amyloid burden and entorhinal tau, while worse immediate free recall scores predicted greater tau in the inferior temporal and entorhinal cortices. In turn, in all carriers, lower free and total recall scores predicted greater amyloid and regional tau pathology.

Conclusions

FCSRT scores were associated with in vivo markers of AD–related pathology in cognitively unimpaired individuals genetically determined to develop dementia. Difficulties on free recall, particularly delayed recall, were evident earlier in the disease trajectory, while difficulties on cued recall were seen only as carriers neared the onset of dementia, consistent with the pathologic progression of the disease. Findings suggest that the FCSRT can be a useful measure to track disease progression in AD.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:280–292.
2.
Quiroz YT, Sperling RA, Norton DJ, et al. Association between amyloid and tau accumulation in young adults with autosomal dominant Alzheimer disease. JAMA Neurol 2018;75:548–556.
3.
Grober E, Veroff AE, Lipton RB. Temporal unfolding of declining episodic memory on the free and cued selective reminding test in the predementia phase of Alzheimer's disease: implications for clinical trials. Alzheimers Dement (Amst) 2018;10:161–171.
4.
Papp KV, Amariglio RE, Mormino EC, et al. Free and cued memory in relation to biomarker-defined abnormalities in clinically normal older adults and those at risk for Alzheimer's disease. Neuropsychologia 2015;73:169–175.
5.
Papp KV, Rentz DM, Orlovsky I, Sperling RA, Mormino EC. Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: the PACC5. Alzheimers Dement 2017;3:668–677.
6.
Schindler SE, Jasielec MS, Weng H, et al. Neuropsychological measures that detect early impairment and decline in preclinical Alzheimer disease. Neurobiol Aging 2017;56:25–32.
7.
Wagner M, Wolf S, Reischies FM, et al. Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease. Neurology 2012;78:379–386.
8.
Lemos R, Duro D, Simões MR, Santana I. The free and cued selective reminding test distinguishes frontotemporal dementia from Alzheimer's disease. Arch Clin Neuropsychol 2014;29:670–679.
9.
Sarazin M, Berr C, De Rotrou J, et al. Amnestic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study. Neurology 2007;69:1859–1867.
10.
Slachevsky A, Barraza P, ornberger M, et al. Neuroanatomical comparison of the “word” and “picture” versions of the free and cued selective reminding test in Alzheimer's disease. J Alzheimers Dis 2018;61:589–600.
11.
Reiman EM, Langbaum JBS, Fleisher AS, et al. Alzheimer's prevention initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis 2011;26(suppl) 321–329.
12.
Acosta-Baena N, Sepulveda-Falla D, Lopera-Gómez CM, et al. Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study. Lancet Neurol 2011;10:213–220.
13.
Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303–308.
14.
Fuller JT, Cronin-Golomb A, Gatchel JR, et al. Biological and cognitive markers of presenilin1 E280A autosomal dominant Alzheimer's disease: a comprehensive review of the Colombian kindred. J Prev Alzheimers Dis 2019;6:112–120.
15.
Fleisher AS, Chen K, Quiroz YT, et al. Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study. JAMA Neurol 2015;72:316–324.
16.
Delgado C, Muñoz-Neira C, Soto A, et al. Comparison of the psychometric properties of the “word” and “picture” versions of the free and cued selective reminding test in a Spanish-speaking cohort of patients with mild Alzheimer's disease and cognitively healthy controls. Arch Clin Neuropsychol 2016;31:165–175.
17.
Logan J, Fowler JS, Volkow ND, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 1990;10:740–747.
18.
Amariglio RE, Mormino EC, Pietras AC, et al. Subjective cognitive concerns, amyloid-beta, and neurodegeneration in clinically normal elderly. Neurology 2015;85:56–62.
19.
Johnson KA, Schultz A, Betensky RA, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol 2016;79:110–119.
20.
Chien DT, Szardenings AK, Bahri S, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J Alzheimers Dis 2014;38:171–184.
21.
Aguirre-Acevedo DC, Lopera F, Henao E, et al. Cognitive decline in a Colombian kindred with autosomal dominant Alzheimer disease: a retrospective cohort study. JAMA Neurol 2016;73:431–438.
22.
Grober E, Lipton R, Wang C. The free and cued selective reminding test predicts Alzheimer's disease neuropathology (P4.1-026). Neurology 2019;92:P4.1–026.
23.
Donohue MC, Sperling RA, Salmon DP, et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol 2014;71:961–970.
24.
Tariot PN, Lopera F, Langbaum JB, et al. The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease trial: a study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohort. Alzheimers Dement 2018;4:150–160.
25.
Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006;112:389–404.
26.
Braak H, Braak E. Diagnostic criteria for neuropathologic assessment of Alzheimer's disease. Neurobiol Aging 1997;18:S85–S88.
27.
Papp KV, Rentz DM, Mormino EC, et al. Cued memory decline in biomarker-defined preclinical Alzheimer disease. Neurology 2017;88:1431–1438.
28.
Auriacombe S, Helmer C, Amieva H, Berr C, Dubois B, Dartigues JF. Validity of the free and cued selective reminding test in predicting dementia: the 3C Study. Neurology 2010;74:1760–1767.
29.
Wheeler MA, Stuss DT, Tulving E. Frontal lobe damage produces episodic memory impairment. J Int Neuropsychol Soc 1995;1:525–536.
30.
Eichenbaum H, Yonelinas AP, Ranganath C. The medial temporal lobe and recognition memory. Annu Rev Neurosci 2007;30:123–152.
31.
Carr VA, Bernstein JD, Favila SE, Rutt BK, Kerchner GA, Wagner AD. Individual differences in associative memory among older adults explained by hippocampal subfield structure and function. Proc Natl Acad Sci USA 2017;114:12075–12080.
32.
Marks SM, Lockhart SN, Baker SL, Jagust WJ. Tau and beta-amyloid are associated with medial temporal lobe structure, function, and memory encoding in normal aging. J Neurosci 2017;37:3192–3201.
33.
Ranganath C, Cohen MX, Dam C, D'Esposito M. Inferior temporal, prefrontal, and hippocampal contributions to visual working memory maintenance and associative memory retrieval. J Neurosci 2004;24:3917–3925.
34.
Guzman-Velez E, Jaimes S, Aguirre-Acevedo DC, et al. A three-factor structure of cognitive functioning among unimpaired carriers and non-carriers of autosomal-dominant Alzheimer's disease. J Alzheimers Dis 2018;65:107–115.

Information & Authors

Information

Published In

Neurology®
Volume 95Number 10September 8, 2020
Pages: e1312-e1321
PubMed: 32611637

Publication History

Received: November 27, 2019
Accepted: March 9, 2020
Published online: July 1, 2020
Published in print: September 8, 2020

Permissions

Request permissions for this article.

Disclosure

E. Guzmán-Vélez receives research funding from the NIA K23AG061276 and NIH Research Supplement for Diversity (DP5OD019833). J. Martínez, K. Papp, and A. Baena report no disclosures relevant to the manuscript. C. Vila-Castelar receives research support from an Alzheimer's Association–Research Fellowship (grant 2019-AARF-644631). A. Artola, A.P. Schultz, Y. Bocanegra, and J. Sanchez report no disclosures relevant to the manuscript. D. Rentz has provided consulting services to the Neurotrack Scientific Advisory Board and Biogen. P.N. Tariot serves on the scientific board and consults for commercial entities (Abbott Laboratories, AbbVie, AC Immune, Amgen, BioGen, Insys, Intracellular Therapeutics, Lilly, Lundbeck, Boehringer-Ingelheim, Chase Pharmaceuticals, Otsuka, T3D, Takeda, Pfizer, Merck, Roche) and nonprofits (W Garfield Weston Foundation, and the California Pacific Medical Center). He is a member of the International Journal of Geriatric Psychiatry Editorial Board. He receives research support from Avanir, Lilly, Merck, Roche, AstraZeneca, Functional Neuromodulation, Genentech, Toyama. Abbott Laboratories, AbbVie, Amgen, BioGen, Lundbeck, Takeda, Pfizer, Novartis, and the NIA (1RFAG041705-01A1 and NIA 1UF1AG046150). E.M. Reiman reports research funding from Genentech/Roche, Novartis/Amgen and Avid/Lilly AVID, as well as NIA RF1 AG041705, NIA UF1 AG046150, NIA R01 AG031581, NIA P30 AG19610, NIA R01 AG055444, NIA R01 AG031581, NIA P30 AG19610, NIA RF1 AG041705, PI, and NIA 1UF1 AG046150, Arizona Department of Health Services (Arizona Alzheimer's Consortium) and state of Arizona (Arizona Alzheimer's Consortium), the Banner Research, University of Arizona, Arizona State University, Translational Genomics Research Institute, Arizona Alzheimer's Consortium, Anonymous Foundation, Flinn Foundation, and NOMIS Foundation. He serves on the advisory board of and consults for Alkahest, Alzheon, Biogen, Denali, Green Valley, United Neuroscience, Zinfandel Roche, and Roche Diagnostics (expenses only). R. Sperling receives research support for NIH grants P01AG036694, P50AG005134, 2009–2020, and U19 AG10483, as well as from Eli Lilly (clinical trial) and the Alzheimer's Association. She is a site principal investigator or coinvestigator for Avid, Bristol-Myers Squibb, Pfizer, and Janssen Alzheimer Immunotherapy clinical trials. She receives travel funding and honoraria from AC Immune, Janssen, and Roche. She consults for Biogen, Roche, AC Immune, Eisai, Takeda, Neurocentria, and Janssen. K.A. Johnson has provided consulting services for Novartis, Biogen, and Eli Lilly; received support from a joint NIH-Lilly–sponsored clinical trial (A4 Study; U19AG10483); and received research support from NIH grants R01 AG027435, P50 AG00513421, AG036694, R01 AG046396, R13 AG042201174210, U19AG10483, and U01AG024904, as well as the Alzheimer Association and Marr Foundation. F. Lopera receives research support from philanthropy, NIA, Genentech, and Roche for the API ADAD Trial. Y.T. Quiroz receives research funding from NIH for RO1AG054671 and DP5OD019833 and from MGH. Go to Neurology.org/N for full disclosures.

Study Funding

This research was supported by the NIH National Institute of Aging (NIA) (RO1AG054671 [Y.T.Q.]) and Office of the Director (DP5OD019833 [Y.T.Q.]), Massachusets General Hospital (MGH) Executive Committee On Research Claflin Distinguished Scholar Award (Y.T.Q.), MGH Physician/Scientist Development Award (YTQ), COLCIENCIAS (Colombia) (F.L), and MGH Executive Committee on Research Fund for Medical Clinical Fellowship Award (E.G.-V.).

Authors

Affiliations & Disclosures

Edmarie Guzmán-Vélez, PhD
From the Departments of Psychiatry (E.G.V., J.M., C.V.-C., A.A., J.S., Y.T.Q.), Neurology (A.P.S., D.R., R.S., K.A.J., Y.T.Q.), and Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Grupo de Neurociencias (A.B., Y.B., F.L., Y.T.Q.), Universidad de Antioquia, Medellín, Colombia; Center for Alzheimer Research and Treatment (K.P., D.R., R.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Boston, MA; and Banner Alzheimer's Institute (P.N.T., E.M.R.), Phoenix, AZ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1) NIA K23, K23AG061276, PI, 2019-2024, (2) NIH Postdoctoral Research Supplement for Diversity, DP5OD019833, PI, 2015-2017
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Jairo Martínez, BA
From the Departments of Psychiatry (E.G.V., J.M., C.V.-C., A.A., J.S., Y.T.Q.), Neurology (A.P.S., D.R., R.S., K.A.J., Y.T.Q.), and Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Grupo de Neurociencias (A.B., Y.B., F.L., Y.T.Q.), Universidad de Antioquia, Medellín, Colombia; Center for Alzheimer Research and Treatment (K.P., D.R., R.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Boston, MA; and Banner Alzheimer's Institute (P.N.T., E.M.R.), Phoenix, AZ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Kate Papp, PhD
From the Departments of Psychiatry (E.G.V., J.M., C.V.-C., A.A., J.S., Y.T.Q.), Neurology (A.P.S., D.R., R.S., K.A.J., Y.T.Q.), and Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Grupo de Neurociencias (A.B., Y.B., F.L., Y.T.Q.), Universidad de Antioquia, Medellín, Colombia; Center for Alzheimer Research and Treatment (K.P., D.R., R.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Boston, MA; and Banner Alzheimer's Institute (P.N.T., E.M.R.), Phoenix, AZ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NIA 1K23AG053422-01, PI NIA P01AG036694, Co-Investigator NIH P30AG062421, pilot project awardee
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Alzheimer's Association, US-POINTER, Co-Investigator
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Ana Baena, MA
From the Departments of Psychiatry (E.G.V., J.M., C.V.-C., A.A., J.S., Y.T.Q.), Neurology (A.P.S., D.R., R.S., K.A.J., Y.T.Q.), and Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Grupo de Neurociencias (A.B., Y.B., F.L., Y.T.Q.), Universidad de Antioquia, Medellín, Colombia; Center for Alzheimer Research and Treatment (K.P., D.R., R.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Boston, MA; and Banner Alzheimer's Institute (P.N.T., E.M.R.), Phoenix, AZ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Clara Vila-Castelar, PhD
From the Departments of Psychiatry (E.G.V., J.M., C.V.-C., A.A., J.S., Y.T.Q.), Neurology (A.P.S., D.R., R.S., K.A.J., Y.T.Q.), and Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Grupo de Neurociencias (A.B., Y.B., F.L., Y.T.Q.), Universidad de Antioquia, Medellín, Colombia; Center for Alzheimer Research and Treatment (K.P., D.R., R.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Boston, MA; and Banner Alzheimer's Institute (P.N.T., E.M.R.), Phoenix, AZ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Alzheiemer's Association - Research Fellowship (Grant # 2019- AARF-644631)
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Arabiye Artola, MS
From the Departments of Psychiatry (E.G.V., J.M., C.V.-C., A.A., J.S., Y.T.Q.), Neurology (A.P.S., D.R., R.S., K.A.J., Y.T.Q.), and Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Grupo de Neurociencias (A.B., Y.B., F.L., Y.T.Q.), Universidad de Antioquia, Medellín, Colombia; Center for Alzheimer Research and Treatment (K.P., D.R., R.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Boston, MA; and Banner Alzheimer's Institute (P.N.T., E.M.R.), Phoenix, AZ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Aaron P. Schultz, PhD
From the Departments of Psychiatry (E.G.V., J.M., C.V.-C., A.A., J.S., Y.T.Q.), Neurology (A.P.S., D.R., R.S., K.A.J., Y.T.Q.), and Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Grupo de Neurociencias (A.B., Y.B., F.L., Y.T.Q.), Universidad de Antioquia, Medellín, Colombia; Center for Alzheimer Research and Treatment (K.P., D.R., R.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Boston, MA; and Banner Alzheimer's Institute (P.N.T., E.M.R.), Phoenix, AZ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1) NIH-NIA, R21-AG060221, PI, 2018-2020 (2) NIH-NIA, P01-AG036694, PL, 2015-2020
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Yamile Bocanegra, PhD
From the Departments of Psychiatry (E.G.V., J.M., C.V.-C., A.A., J.S., Y.T.Q.), Neurology (A.P.S., D.R., R.S., K.A.J., Y.T.Q.), and Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Grupo de Neurociencias (A.B., Y.B., F.L., Y.T.Q.), Universidad de Antioquia, Medellín, Colombia; Center for Alzheimer Research and Treatment (K.P., D.R., R.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Boston, MA; and Banner Alzheimer's Institute (P.N.T., E.M.R.), Phoenix, AZ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
From the Departments of Psychiatry (E.G.V., J.M., C.V.-C., A.A., J.S., Y.T.Q.), Neurology (A.P.S., D.R., R.S., K.A.J., Y.T.Q.), and Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Grupo de Neurociencias (A.B., Y.B., F.L., Y.T.Q.), Universidad de Antioquia, Medellín, Colombia; Center for Alzheimer Research and Treatment (K.P., D.R., R.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Boston, MA; and Banner Alzheimer's Institute (P.N.T., E.M.R.), Phoenix, AZ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
From the Departments of Psychiatry (E.G.V., J.M., C.V.-C., A.A., J.S., Y.T.Q.), Neurology (A.P.S., D.R., R.S., K.A.J., Y.T.Q.), and Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Grupo de Neurociencias (A.B., Y.B., F.L., Y.T.Q.), Universidad de Antioquia, Medellín, Colombia; Center for Alzheimer Research and Treatment (K.P., D.R., R.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Boston, MA; and Banner Alzheimer's Institute (P.N.T., E.M.R.), Phoenix, AZ.
Disclosure
Scientific Advisory Boards:
1.
Neurotrack, Biogen
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Neurotrack for consulting on scientific advisory board
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Biogen, Neurotrack
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Neurotrack
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
From the Departments of Psychiatry (E.G.V., J.M., C.V.-C., A.A., J.S., Y.T.Q.), Neurology (A.P.S., D.R., R.S., K.A.J., Y.T.Q.), and Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Grupo de Neurociencias (A.B., Y.B., F.L., Y.T.Q.), Universidad de Antioquia, Medellín, Colombia; Center for Alzheimer Research and Treatment (K.P., D.R., R.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Boston, MA; and Banner Alzheimer's Institute (P.N.T., E.M.R.), Phoenix, AZ.
Disclosure
Scientific Advisory Boards:
1.
Commercial - Abbott Laboratories, AbbVie, AC Immune, Amgen, BioGen, Insys, Intracellular Therapeutics, Lilly, Lundbeck, Boehringer-Ingelheim, Chase Pharmaceuticals, Otsuka, T3D, Takeda, Pfizer, Merck, Roche. Non-profit - W Garfield Weston Foundation, California Pacific Medical Center.
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Commercial - Abbott Laboratories, AbbVie, AC Immune, Amgen, BioGen, Insys, Intracellular Therapeutics, Lilly, Lundbeck, Boehringer-Ingelheim, Chase Pharmaceuticals, Otsuka, T3D, Takeda, Pfizer, Merck, Roche. Non-profit - W Garfield Weston Foundation, California Pacific Medical Center.
Editorial Boards:
1.
Member of
Patents:
1.
U.S. Patent # 11/632,747, “Biomarkers of Neurodegenerative disease.”
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
Commercial - Banner Health
Consultancies:
1.
Commercial - Abbott Laboratories, AbbVie, AC Immune, Amgen, BioGen, Insys, Intracellular Therapeutics, Lilly, Lundbeck, Boehringer-Ingelheim, Chase Pharmaceuticals, Otsuka, T3D, Takeda, Pfizer, Merck, Roche. Non-profit - W Garfield Weston Foundation, California Pacific Medical Center.
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
Stock options in Adamas Pharmaceticals
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Commercial - Avanir, Lilly, Merck, Roche, AstraZeneca, Functional Neuromodulation (f(nm)), Genentech, Toyama. Abbott Laboratories, AbbVie, Amgen, BioGen, Lundbeck, Takeda, Pfizer, Novartis.
Research Support, Government Entities:
1.
National Institute on Aging- 1RFAG041705-01A1 Alzheimer’s Prevention Initiative Principal Investigators: F. Lopera, E. Reiman, P. Tariot 5/18/12-4/30/17 National Institute on Aging- 1UF1AG046150 Alzheimer’s Prevention Initiative APOE4 trial Principal Investigators: E. Reiman, P. Tariot 9/20/13-8/31/18
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
Stocks options for Adamas
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
From the Departments of Psychiatry (E.G.V., J.M., C.V.-C., A.A., J.S., Y.T.Q.), Neurology (A.P.S., D.R., R.S., K.A.J., Y.T.Q.), and Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Grupo de Neurociencias (A.B., Y.B., F.L., Y.T.Q.), Universidad de Antioquia, Medellín, Colombia; Center for Alzheimer Research and Treatment (K.P., D.R., R.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Boston, MA; and Banner Alzheimer's Institute (P.N.T., E.M.R.), Phoenix, AZ.
Disclosure
Scientific Advisory Boards:
1.
Alkahest, Alzheon, Biogen, Denali, Green Valley, United Neuroscience and Zinfandel Roche and Roche Diagnostics (expenses only)
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
Use of biomarker endpoints in persons at risk to evaluation Alzheimer's prevention therapies(through Banner Health)
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
See 1 above.
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Genentech/Roche, Novartis/Amgen and Avid/Lilly
Research Support, Government Entities:
1.
NIA RF1 AG041705 (PI) NIA UF1 AG046150 (PI) NIA R01 AG031581 (PI) NIA P30 AG19610 (PI) NIA R01 AG055444 (PI) NIA (R01 AG031581, PI) NIA (P30 AG19610, PI) NIA (RF1 AG041705, PI) NIA (1UF1 AG046150, PI) Arizona Department of Health Services (Arizona Alzheimer's Consortium, PI) State of Arizona (Arizona Alzheimer's Consortium, PI)
Research Support, Academic Entities:
1.
Banner Research, University of Arizona, Arizona State University, Translational Genomics Research Institute and Arizona Alzheimer's Consortium
Research Support, Foundations and Societies:
1.
Banner Alzheimer's Foundation Alzheimer's Association Anonymous Foundation Flinn Foundation NOMIS Foundation Stock/Stock Options, Medical Equipment & Materials: Alzheon, Alkahest, Denali and United Neuroscience Wife: Gilead (former employee) and Takeda (employee)
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Reisa Sperling, MD
From the Departments of Psychiatry (E.G.V., J.M., C.V.-C., A.A., J.S., Y.T.Q.), Neurology (A.P.S., D.R., R.S., K.A.J., Y.T.Q.), and Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Grupo de Neurociencias (A.B., Y.B., F.L., Y.T.Q.), Universidad de Antioquia, Medellín, Colombia; Center for Alzheimer Research and Treatment (K.P., D.R., R.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Boston, MA; and Banner Alzheimer's Institute (P.N.T., E.M.R.), Phoenix, AZ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Commercial - AC Immune, travel Commercial - Janssen, honorarium Commercial - Roche, travel, honorarium Commercial - Novartis (spouse) Commercial - AC Immune (spouse) Commercial - Janssen (spouse)
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Personal: 1) Biogen, commercial 2) Roche, commercial, 3) AC Immune, commercial, 4) Eisai, commercial, 5) Takeda, 6) Neurocentria, 7) Janssen Spouse: 1) Novartis, 2) AC Immune, 3) Janssen
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Eli Lilly- clinical trial support 2014-present Eisai - clinical trial support 2020-present
Research Support, Government Entities:
1.
1) National Institute on Aging P01AG036694, principal investigator, 2010-2020; 2) National Institute on Aging P50AG005134, 2009-2020; 3) National Institute on Aging U19 AG10483, Project Leader A4 trial, 2012-2018.
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Alzheimer's Association, co-principal investigator, 2016-2020.
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Keith A. Johnson, MD
From the Departments of Psychiatry (E.G.V., J.M., C.V.-C., A.A., J.S., Y.T.Q.), Neurology (A.P.S., D.R., R.S., K.A.J., Y.T.Q.), and Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Grupo de Neurociencias (A.B., Y.B., F.L., Y.T.Q.), Universidad de Antioquia, Medellín, Colombia; Center for Alzheimer Research and Treatment (K.P., D.R., R.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Boston, MA; and Banner Alzheimer's Institute (P.N.T., E.M.R.), Phoenix, AZ.
Disclosure
Scientific Advisory Boards:
1.
Novartis Biogen AC Immune Roche Lilly/Avid Jannsen
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Novartis Biogen Lilly
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Janssen Cerveau
Research Support, Government Entities:
1.
NIH/NIA: R01 AG027435, PI, 2015 P50 AG00513421, co-I; 2002-date; AG036694 PI; 2009-date; R01 AG046396 PI; 2014-date R13 AG042201174210 PI; 2012-date U19AG10483; Co-I; 2012-date U01AG024904; Co-I; 2015-date
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Alzheimer Association Marr Foundation
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Francisco Lopera, MD
From the Departments of Psychiatry (E.G.V., J.M., C.V.-C., A.A., J.S., Y.T.Q.), Neurology (A.P.S., D.R., R.S., K.A.J., Y.T.Q.), and Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Grupo de Neurociencias (A.B., Y.B., F.L., Y.T.Q.), Universidad de Antioquia, Medellín, Colombia; Center for Alzheimer Research and Treatment (K.P., D.R., R.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Boston, MA; and Banner Alzheimer's Institute (P.N.T., E.M.R.), Phoenix, AZ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
I am principal investigator in a GRANT
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
BANNER INSTITUTE GENENTECH
Research Support, Government Entities:
1.
COLCIENCIAS GRANT NIH
Research Support, Academic Entities:
1.
UNIVERSITY OF ANTIOQUIA (ACADEMIC ENTITY)
Research Support, Foundations and Societies:
1.
FIDELITY FOUNDATION
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
From the Departments of Psychiatry (E.G.V., J.M., C.V.-C., A.A., J.S., Y.T.Q.), Neurology (A.P.S., D.R., R.S., K.A.J., Y.T.Q.), and Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Grupo de Neurociencias (A.B., Y.B., F.L., Y.T.Q.), Universidad de Antioquia, Medellín, Colombia; Center for Alzheimer Research and Treatment (K.P., D.R., R.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Boston, MA; and Banner Alzheimer's Institute (P.N.T., E.M.R.), Phoenix, AZ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Associate Editor for the Journal of Alzheimer's Disease, 2019
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NIH-OD Office of the Director, 1DP5OD019833, Principal Investigator, 09/2014-08/2019 NIH-NIA, R01AG054671, Principal Investigator, 09/2018-08/2023
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE

Notes

Correspondence Dr. Quiroz [email protected]
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Cholinergic-like neurons and cerebral spheroids bearing the PSEN1 p.Ile416Thr variant mirror Alzheimer's disease neuropathology, Scientific Reports, 13, 1, (2023).https://doi.org/10.1038/s41598-023-39630-4
    Crossref
  2. Associations of category fluency clustering performance with in vivo brain pathology in autosomal dominant Alzheimer’s disease , Journal of the International Neuropsychological Society, (1-7), (2023).https://doi.org/10.1017/S1355617723000243
    Crossref
  3. The Multi-Partner Consortium to Expand Dementia Research in Latin America (ReDLat): Driving Multicentric Research and Implementation Science, Frontiers in Neurology, 12, (2021).https://doi.org/10.3389/fneur.2021.631722
    Crossref
  4. Longitudinal amyloid and tau accumulation in autosomal dominant Alzheimer’s disease: findings from the Colombia-Boston (COLBOS) biomarker study, Alzheimer's Research & Therapy, 13, 1, (2021).https://doi.org/10.1186/s13195-020-00765-5
    Crossref
  5. Current directions in tau research: Highlights from Tau 2020, Alzheimer's & Dementia, 18, 5, (988-1007), (2021).https://doi.org/10.1002/alz.12452
    Crossref
Loading...

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

Purchase this article to get full access to it.

Purchase Access, $39 for 24hr of access

View options

Short Form

View Short Form

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share